This report insight is based on “C. Barnes & Co.: 2026 Global Brain-Computer Interface Market Panorama Analysis Report,” “Shanghai Jiao Tong University: Brain-Computer Interface 2025: The Year of Industrial Takeoff Report,” and the end of the article with 50+ brain-computer interface industry research reports and data. The complete report data charts and the latest reference report bundle at the end of the article have been shared in the exchange group. Read the original text to view, join the group for consultation, customize data and reports, and grow together with 800+ industry professionals. We will dissect the development logic and implementation opportunities of the brain-computer interface industry from multiple dimensions—market size, industry landscape, technology routes, clinical progress, and capital dynamics—to provide actionable decision-making references for practitioners, investors, and entrepreneurs.

The Global Brain-Computer Interface Industry Enters a Critical Point of Explosion, with Market Size Sustaining High Growth

2025 is widely defined by the industry as the first year of the brain-computer interface industry. Its core logic is not simply hype over a technology concept, but that market demand and technology maturity have both reached the critical point for industrial implementation. Over the past few years, global BCI technology has achieved continuous breakthroughs in signal acquisition, intelligent decoding, and closed-loop neuromodulation; clinical safety and efficacy have been validated in multiple trials; and application scenarios have extended from serious medicine to consumer electronics and industrial control, accelerating the maturity of the industry ecosystem. Driven by both the rigid medical demand of global markets—such as neurological rehabilitation and functional substitution—and the expansion of consumer-grade human-computer interaction scenarios, the global market shows a trend of sustained high-speed growth. China, in particular, with its huge patient base, complete supply chain system, and continuous policy support, has become the fastest-growing regional market globally.

The dual-axis chart 1 of global and China BCI market size trends, with data EXCEL and chart PDF templates, has been shared to the members group
The global BCI market size will grow from USD 2.14 billion in 2024 to USD 12.4 billion in 2034, while China’s market size is expected to grow from RMB 1.73 billion in 2023 to RMB 3.89 billion in 2027.
3-Second Read: The global market has nearly 6x growth potential over a decade, and the Chinese market will double in size within 4 years. The industry as a whole is in the early stage of high-speed growth.
Action Recommendations by Audience: Medical device manufacturers can plan core technology R&D ahead of time to capture the industry dividends from market expansion; investors can focus on early-stage projects with clinical implementation capabilities within the track to seize early growth opportunities; entrepreneurs can focus on application implementation in niche scenarios, avoiding the red-ocean competition of core hardware.
Data on the size and growth rate of segment markets in various countries can be obtained by joining the group for the complete report.

Global Industry Landscape: Dual-Core Driven by China and the US, with a Clearly Differentiated Industry Chain Structure

The competitive landscape of the global brain-computer interface industry has clearly shown a dual-core driven characteristic by China and the US. The two countries are both in the global first tier in research output, enterprise count, clinical progress, and capital investment, together accounting for over half of the global market share and core enterprise resources. From the perspective of the industry chain structure, the industry shows a clear “dumbbell-shaped” feature, and the differences in enterprise distribution across upstream and downstream segments directly determine the competitive barriers, profit margins, and entry thresholds of different segments.

The horizontal bar chart 2 of global BCI enterprise regional distribution, with data EXCEL and chart PDF templates, has been shared to the members group
Among global BCI enterprises, US enterprises account for 34% and Chinese enterprises account for 22%, with the two countries together accounting for over half, forming a dual-core global industry landscape.
3-Second Read: The US continues to lead in frontier technology exploration and clinical implementation progress, while the Chinese market is catching up rapidly. The two countries control the vast majority of the industry’s core resources and discourse power.
Action Recommendations by Audience: Domestic enterprises can strengthen industry-university-research cooperation with top scientific research institutions in China and the US to quickly make up for technology shortcomings; overseas-expanding enterprises can prioritize emerging markets such as Southeast Asia and the Middle East to avoid head-on competition with top European and American enterprises; policymakers can further improve the industry-university-research transformation mechanism to promote core technology breakthroughs of local enterprises.
From the perspective of the entire industry chain, the BCI industry can be divided into three segments: upstream core components, midstream system integration and software algorithms, and downstream scenario applications and services. The enterprise distribution and competitive landscape differ significantly across segments.

The donut chart 3 of global BCI industry chain distribution, with data EXCEL and chart PDF templates, has been shared to the members group
In the global BCI industry chain, downstream application enterprises account for as high as 70% of the total, midstream system integrators account for 20%, and upstream core component enterprises account for only 10%.
3-Second Read: The downstream application segment has low barriers and enterprises crowd into competition, while the upstream core technology has high barriers and scarce enterprises, making it the bottleneck core segment of the entire industry chain.
Action Recommendations by Audience: Research teams with technology accumulation can focus on R&D of upstream core components such as electrodes and chips to enjoy the market premium brought by high barriers; midstream enterprises can strengthen upstream-downstream resource integration to build integrated software and hardware solutions; downstream enterprises can deeply cultivate niche medical scenarios to build clinical data barriers and avoid homogeneous low-price competition.
The analysis report on the list of core enterprises and technology barriers in each industry chain segment can be obtained by joining the group for the complete version.

Technology Routes and Application Scenarios: Medical as the Foundation, Consumer Breaking Through

The choice of BCI technology route is essentially a trade-off among signal quality, invasion risk, and usage threshold. The industry is currently divided into three major routes: invasive, semi-invasive, and non-invasive, and different technology routes correspond to different commercialization scenarios and implementation paces. From the application side, the medical scenario is the core foundation of current industry commercialization, while the consumer-grade scenario shows strong growth potential and has become the industry’s second growth curve.

The semi-donut chart 4 of BCI downstream application share, with data EXCEL and chart PDF templates, has been shared to the members group
Among BCI downstream enterprises, medical applications account for 56% and non-medical applications account for 44%.
3-Second Read: Medicine is the main battlefield of current industry commercialization, while non-medical scenarios are rapidly rising in volume. The future industry will form a dual-engine growth pattern of medical + consumer.
Action Recommendations by Audience: Medical enterprises can prioritize rigid-demand scenarios such as neurological rehabilitation and motor function substitution to accelerate clinical trials and registration approval progress; consumer electronics enterprises can start from lightweight scenarios such as sleep monitoring and focus training to lower user barriers; content vendors can plan the content ecosystem for BCI interaction ahead of time to seize the first-mover advantage in consumer-grade scenarios.
From the perspective of the market structure of technology routes, the commercialization progress of different routes differs significantly. Non-invasive technology has become the mainstream choice in the current market by virtue of its own advantages.

The gray-background bar chart 7 of non-invasive BCI share, with data EXCEL and chart PDF templates, has been shared to the members group
Non-invasive BCI currently accounts for 82% of the Chinese market.
3-Second Read: Non-invasive, with the advantages of high safety, low cost, and low usage threshold, has become the mainstream of the current market, while invasive has irreplaceable value in high-end medical scenarios and is the long-term technology commanding height of the industry.
Action Recommendations by Audience: Startups can prioritize the non-invasive technology route to quickly achieve product implementation and commercial payback; enterprises with medical resources can simultaneously lay out the invasive technology route to seize the long-term technology commanding height; channel vendors can focus on promoting non-invasive rehabilitation products to quickly open the C-end and primary medical markets.
The product comparison and commercialization path analysis report for different technology routes can be obtained by joining the group.

Clinical Implementation Accelerates, 2024–2025 Becomes a Key Milestone for Industrialization

Clinical trials are the only way for BCI technology to move from the laboratory to commercialization, and the core link to verify product safety and efficacy. Since 2024, the number of global BCI clinical trials has shown explosive growth, especially in the Chinese market, where the number of clinical trials has increased substantially, marking that the domestic BCI industry has officially entered the critical stage of clinical validation. Multiple products are expected to complete registration approval and achieve scaled market launch within the next 1-2 years.

The line chart 5 of China BCI annual clinical trial trend, with data EXCEL and chart PDF templates, has been shared to the members group
The number of annual BCI clinical trials in China grew from 11 in 2023 to 31 in 2024, and reached 18 in the first half of 2025.
3-Second Read: 2024 was the first year of domestic BCI clinical explosion, with the number of clinical trials nearly tripling and the industry implementation pace greatly accelerated.
Action Recommendations by Audience: Medical device manufacturers can accelerate the layout and promotion of clinical trials to seize the first-mover advantage of registration approval; clinical institutions can strengthen cooperation with enterprises, participate in multi-center clinical trials, and accumulate clinical data; investors can focus on enterprises that have entered the key stage of clinical trials to reduce the uncertainty risk of technology implementation.
From 2024 to 2025, the global BCI field achieved multiple key clinical and technological breakthroughs, with both overseas leaders and domestic enterprises delivering impressive results, and the global industry officially entered the race for clinical implementation.

The timeline chart 6 of global BCI key milestones, with data EXCEL and chart PDF templates, has been shared to the members group
From 2024 to 2025, the global BCI field achieved multiple key breakthroughs: Neuralink completed the first human implant and achieved over 10 global implants, while domestic enterprises such as 博睿康 and 脑虎科技 also successively completed the first human implant and key breakthroughs such as real-time Chinese language decoding.
3-Second Read: Overseas enterprises continue to lead in implant count and scenario expansion, while domestic enterprises achieve characteristic breakthroughs in localized scenarios (such as Chinese language decoding). The global industry has entered the race for clinical implementation.
Action Recommendations by Audience: Domestic enterprises can focus on technological innovation for localized needs to form differentiated competitive advantages; clinical institutions can establish standardized BCI surgery and rehabilitation processes to improve clinical transformation efficiency; industry associations can accelerate the formulation of clinical standards to regulate long-term industry development.
The complete list of global BCI clinical trials and progress tracking report can be obtained by joining the group for the real-time updated version.

Capital Market Enthusiasm Rises, Policy Catalyzes Long-Term Industry Development

The rapid development of the BCI industry cannot be separated from the support of the capital market and the continuous empowerment of the policy side. Under the catalysis of multiple policy benefits—such as the “15th Five-Year Plan” listing BCI as a future industry and the National Healthcare Security Administration setting up special charge items—the domestic capital market’s attention to the BCI sector has continued to rise. Related listed companies’ stock prices have performed strongly, and primary market financing has continued to concentrate on enterprises with clinical implementation capabilities. The injection of capital has further accelerated the industry’s technology iteration and commercialization process.

The timeline chart 8 of BCI concept stock gains, with data EXCEL and chart PDF templates, has been shared to the members group
Since the beginning of 2025, the stock prices of A-share/H-share BCI-related listed companies have generally risen sharply, among which 创新医疗 rose 170%, 心玮医疗 rose 119%, and 翔宇医疗 rose 89%.
3-Second Read: Policy benefits continue to be released, and the capital market’s recognition of the BCI track has greatly increased. Enterprises with core technology and implementation capabilities are more favored by capital.
Action Recommendations by Audience: Investors can focus on listed companies that lay out invasive core technology and have entered the clinical stage, as well as consumer-grade product enterprises with rehabilitation channel advantages; listed companies can accelerate the layout of BCI business through industry-university-research cooperation and M&A integration; enterprises to be listed can sort out clinical progress and commercialization paths in advance to meet the core needs of the capital market.
The primary market financing data and key enterprise valuation analysis report for the BCI track can be obtained by joining the group.

Core Insights and Implementation Recommendations

Comparison Table of Core Conclusions from Different Institution Reports

Report Name	Core Conclusion	Core Data Differences	Reason Analysis
C. Barnes & Co.: 2026 Global Brain-Computer Interface Market Panorama Analysis Report	In the 2026 global BCI market, China’s market size reaches USD 1.053 billion, making it one of the largest single-country markets globally, with a CAGR of 21.6% from 2026 to 2032	The estimate for China’s 2026 market size is USD 1.053 billion (approx. RMB 7.446 billion), higher than other brokerage reports’ RMB 3.89 billion (2027)	1. Different statistical scope: this report counts the market size of the entire industry chain, including upstream components, midstream system integration, and downstream applications and services; brokerage reports mostly focus on terminal product market size; 2. Different time periods: this report’s data are 2026 forecast values, while brokerage reports are mostly 2027 forecasts; 3. Exchange rate conversion differences
Shanghai Jiao Tong University: Brain-Computer Interface 2025: The Year of Industrial Takeoff Report	2025 is the first year of the BCI industry, with the sector shifting from leading technology prototypes to leading clinical evidence, and medical scenarios achieving scaled clinical application breakthroughs first	As of December 2025, the number of registered BCI clinical trials in China reached 95, higher than the 18 counted by Arterial Network in the first half of 2025	1. Different statistical time: this report counts up to December 2025, while Arterial Network data is up to June 2025; 2. Different statistical caliber: this report includes exploratory and registered clinical trials, while Arterial Network mostly counts formally registered clinical trials
China Merchants Securities: Innovative Devices Series Thematic Research Report (II)	BCI downstream applications are dominated by medical use at 56%, with non-medical scenarios at 44%; consumer-grade scenarios have greater growth potential in the future	Consistent with the CAICT industry chain enterprise distribution data, no core differences, only minor differences in segment scenario proportions	Consistent statistical caliber, both based on downstream enterprise application scenario distribution statistics; segment differences stem from different classification boundaries for consumer-grade scenarios
Everbright Securities: Brain-Computer Interface Industry Series Research II	Globally, China and US BCI enterprises together account for over 50%, while upstream core component enterprises in the chain account for only 10%, with high technical barriers	Consistent with CAICT data, no core differences	Data sources are all CAICT, consistent statistical caliber, both being regional and industry-chain segment distributions of global BCI-related enterprises

3 Actionable Things

1. For medical-scenario entrepreneurs, complete needs research at the rehabilitation department of a local top-tier hospital next week, focusing on understanding the core needs and pain points of stroke and spinal cord injury patients regarding BCI rehabilitation devices, and produce more than 10 valid interview records.
2. For investors, complete in-depth due diligence on 3 BCI enterprises that have entered the clinical trial stage next week, focusing on verifying their clinical data, registration approval progress, and core technology patents, and produce a complete due diligence brief.
3. For medical device manufacturers, connect with 2 leading domestic neuroscience research institutions next week to discuss industry-academia-research collaboration, clarify the technical optimization direction for non-invasive BCI rehabilitation products, and sign a preliminary cooperation framework.

Risk Warnings and Response Plans

First risk: Industry reports often emphasize the technology prospects and market space of BCI but do not mention the clinical approval risk of invasive BCI. Currently, no invasive BCI product has been approved for market in China, and serious adverse events that may occur in clinical trials can directly lead to product approval failure, or even expose enterprises to huge compensation.
Specific response plan: Enterprises need to complete sufficient animal experiments and safety verification before clinical trials, establish a sound adverse event contingency plan, and prioritize product paths with a small indication scope and controllable risk for registration filing; our community has senior medical device registration experts who can provide one-on-one registration path planning and risk assessment services.
Second risk: Industry reports mention the growth potential of consumer-grade BCI but do not explain the signal quality bottleneck of non-invasive BCI. Current consumer-grade products generally suffer from low signal-to-noise ratio and poor anti-interference capability, and the actual user experience falls far short of the promotional effect, easily triggering user complaints and reputation collapse.
Specific response plan: Consumer-grade product enterprises need to prioritize scenarios with lower signal precision requirements such as sleep monitoring and focus training, improve product stability through multimodal signal fusion, and avoid over-promoting product functions; our community has technical experts in signal processing who can provide consulting and support for product technology optimization.
Third risk: Industry reports emphasize policy empowerment for the industry but do not mention the ethical regulation and data security risks related to BCI. Brain signals are personal sensitive biometric information, and the current domestic compliance management policy for brain data is not yet complete. If enterprises manage data non-compliantly, they may face regulatory penalties or even have their business suspended.
Specific response plan: Enterprises need to establish a sound compliance system for brain data collection, storage, and use, strictly follow the requirements of the Personal Information Protection Law, anonymize user data, and engage with regulators in advance to understand policy direction; our community has network security and data compliance lawyers who can provide professional services for building data compliance systems.

Summary of Core Data Tables

Table 1: Global and China BCI Market Size Data

Year	Global Market Size (USD 100 million)	China Market Size (RMB 100 million)
2019	12	–
2023	20	17.3
2024	21.4	22.1
2025	29.4	–
2026	32.8	–
2027	37.2	38.9
2029	76.3	–
2034	124	–

Table 2: Global BCI Enterprise Regional Distribution Data

Region	Enterprise Count Share (%)
United States	34
China	22
Others	44

Table 3: Global BCI Industry Chain Enterprise Distribution Data

Industry Chain Segment	Enterprise Count Share (%)
Upstream	10
Midstream	20
Downstream	70

Table 4: BCI Downstream Application Enterprise Distribution Data

Application Type	Enterprise Count Share (%)
Medical	56
Non-medical	44

Table 5: China Annual BCI Clinical Trial Count Data

Year	Clinical Trial Count (items)
2020	8
2021	11
2022	12
2023	11
2024	31
2025	18

Table 6: 2024–2025 Global BCI Key Milestone Data

Milestone Event	Year
Neuralink completes first human implant	2024
博睿康 NEO system domestic first implant	2024
脑虎科技 achieves real-time Chinese language decoding	2024
Synchron achieves brain-controlled iPad	2025
Neuralink global implants exceed 10 cases	2025
阶梯医疗 completes first human clinical trial	2025

Table 7: Non-invasive BCI Market Share Data

Technology Type	Market Share (%)
Non-invasive	82
Invasive/Semi-invasive	18

Table 8: BCI-related Listed Companies Gain Data Since Early 2025

Listed Company	Gain (%)
创新医疗	170
心玮医疗	119
翔宇医疗	89
博拓生物	71
麦澜德	69
荣泰健康	64
爱朋医疗	61
乐普医疗	46

---

List of Data Charts in This Article

1. Chart 1: Global and China BCI Market Size Trend Dual-Axis Chart
2. Chart 2: Global BCI Enterprise Regional Distribution Horizontal Bar Chart
3. Chart 3: Global BCI Industry Chain Distribution Donut Chart
4. Chart 4: BCI Downstream Application Share Semi-Donut Chart
5. Chart 5: China BCI Clinical Trial Annual Trend Line Chart
6. Chart 6: Global BCI Key Milestone Timeline Chart
7. Chart 7: Non-invasive BCI Share Gray-Background Bar Chart
8. Chart 8: BCI Concept Stocks Gain Timeline Chart

Reference Reports (PDF) Directory in This Topic

• BCI Series Report: Insights from Neuralink.pdf
• 2026-02-24 14:50
• Future Industry of BCI: Capital and Policy Empowerment, Welcoming the Industry Window Period.pdf
• 2026-02-24 14:49
• BCI Industry In-Depth Report — Top-level Strategic Support, Domestic BCI Technology Enters Fast Development Lane.pdf
• 2026-02-21 09:13
• Innovative Devices Series Thematic Research Report (II): BCI Topic, Century of Exploration Welcomes Qualitative Change, BCI Industry Explosion Critical Point Approaching.pdf
• 2026-02-09 14:20
• Biomedical Industry Innovative Devices Series Thematic Research Report (II) — BCI Topic: Century of Exploration Welcomes Qualitative Change, BCI Industry Explosion Critical Point Approaching.pdf
• 2026-02-06 16:42
• Barnes: 2026 Global Brain-Computer Interface Market Panorama Analysis Report (English Version).pdf
• 2026-01-30 16:02
• Huachuang Medical Devices Quest Series 11: BCI Industry: Policy Intensifies, Clinical Accelerates, Industrialization Enters Key Stage.pdf
• 2026-01-28 15:51
• BCI Industry In-Depth: Domestic Status, Market Space, Industry Chain and Related Companies Deep Analysis.pdf
• 2026-01-27 15:48
• Shanghai Jiao Tong University: Brain-Computer Interface 2025: The Year of Industrial Takeoff Report.pdf
• 2026-01-21 16:15
• China Merchants Securities: BCI Industry Report — Industry Development Welcomes Golden Period, Blue Ocean Market Vast.pdf
• 2026-01-15 15:33
• BCI Industry Series Research II: From Repairing the Brain to Enhancing Humans, the 15th Five-Year Plan Policy Empowers Trillion-Dollar Market Rise.pdf
• 2026-01-15 15:32
• BCI Thematic Report: Technology Breakthrough and Commercialization Resonance, Watch the BCI Future Industry.pdf
• 2026-01-15 15:32
• 2025 BCI Industry Development Status, Support Policies, Clinical Situation and Industry Progress Analysis Report.pdf
• 2026-01-14 16:19
• Pharmaceutical and Biological Industry In-Depth Report: “15th Five-Year Plan” Draws New Blueprint, BCI Enters Industrialization Fast Lane.pdf
• 2026-01-14 16:07
• BCI Industry Series Research II: From Repairing the Brain to Enhancing Humans, the 15th Five-Year Plan Policy Empowers Trillion-Dollar Market Rise.pdf
• 2026-01-11 09:25
• BCI Industry In-Depth Report: Decoding the Brain Interaction Password, Opening the Human-Machine Collaboration Era.pdf
• 2026-01-08 21:37
• Pharmaceutical and Biological Industry Thematic Research: BCI Policy Empowerment, Industry Trend Clear.pdf
• 2026-01-07 10:28
• Sinolink Securities: Pharmaceutical and Health Industry Research: Policy Promotes Innovative Device Application, BCI Accelerates Commercial Landing.pdf
• 2025-12-30 14:37
• Kingdee (Han Bicheng): 2025 BCI Empowering Enterprise ESG Management Innovation Report.pdf
• 2025-11-28 15:34
• China Post Securities: BCI Industry In-Depth Report: Brain Science Industry and Policy Trend Resonance.pdf
• 2025-11-15 15:03
• Medical Devices Topic: BCI Industry In-Depth Topic II: Three Dimensions to View BCI Industry Development Trends.pdf
• 2025-11-08 17:40
• BCI Industry In-Depth Series Report — “15th Five-Year Plan” Key Track, BCI Expected to Welcome New Opportunities.pdf
• 2025-10-26 08:50
• Everbright Securities – BCI Industry Research Report: Decoding the Brain Interaction Password, Opening the Human-Machine Collaboration Era.pdf
• 2025-09-27 19:52
• China’s Brain Science and BCI Industry Development Status and Suggestions.pdf
• 2025-09-15 15:48
• Computer Industry Thematic Research — Technology Progress and Policy Support Dual Resonance, BCI Industry Promising Future.pdf
• 2025-08-15 15:59
• CAICT: BCI Technology and Application Research Report (2025).pdf
• 2025-08-14 16:57
• BCI Patent Key Technology White Paper.pdf
• 2025-07-27 17:25
• Pharmaceutical Industry 2025 Mid-term Investment Strategy — BD Accelerates Innovative Drug Revaluation, Continued Optimism on Innovative Drugs and Industry Chain, AI Healthcare, BCI and Other Structural Opportunities.pdf
• 2025-07-23 16:22
• 2025 BCI Market Size Application Fields Support Policies and Beneficiary Targets Analysis Report.pdf
• 2025-07-16 16:09
• Computer Industry In-Depth Report: BCI: From Concept to Landing, Opening a New Era of Interaction.pdf
• 2025-07-13 08:27
• Industry Track and Thematic Investment Weathervane: Deep-Sea Technology, Stablecoins, and BCI.pdf
• 2025-07-06 08:29
• China Post Securities – BCI In-Depth Report: Science Fiction into Reality, Industry Landing Accelerates.pdf
• 2025-06-25 16:27
• BCI: From Simple Decoding to Interactive Learning.pdf
• 2025-03-15 15:28
• Medical Devices Topic of BCI: China BCI Industry Status and Outlook.pdf
• 2025-03-05 15:13
• 2025 BCI Blue Book: The Future is Coming, Building a New Paradigm of Human-Computer Interaction – Qianzhan Research Institute.pdf
• 2025-02-11 15:53
• Zheshang Securities – BCI Report: BCI: Human-Machine Exchange in Robots.pdf
• 2024-12-19 15:30
• Guohai Securities – BCI Industry Thematic Research: BCI “Singularity” Approaching, Watch Applications in Rehabilitation Medicine and Depression.pdf
• 2024-07-08 12:09
• BCI Industry In-Depth Report — BCI: The Future is Coming.pdf
• 2024-06-17 10:38
• Shao Yangxue 2024 VBEF Speech: 2024 BCI Research Progress and Clinical Application Research Analysis Report (Brain Science Innovation Development Forum).pdf
• 2024-05-21 14:50
• Eggshell Research Institute: 2024 BCI Research Progress and Clinical Application Research Analysis Report.pdf
• 2024-05-08 14:43
• Tianfeng Pharmaceutical Industry Frontier Thematic Series Research: BCI Industry: Eve of Full Bloom, Future Has Arrived.pdf
• 2024-04-07 10:09
• Tianfeng Securities – Tianfeng Pharmaceutical Industry Frontier Thematic Series Research: BCI Industry: Eve of Full Bloom, Future Has Arrived.pdf
• 2024-04-02 10:30
• BCI Industry Report: The Fusion Future of Human Brain and Digital World.pdf
• 2024-03-17 13:15
• BCI In-Depth Report – QbitAI.pdf
• 2024-02-09 10:22
• Software and Services Industry BCI In-Depth Report: Past the Technology Argumentation Period, Entering the Dawn of Industrialization.pdf
• 2024-02-04 14:23
• BCI Technology Development and Application Research Report (2023).pdf
• 2023-12-28 10:50
• 2023 BCI Report – Tsinghua PBCSF.pdf
• 2023-12-26 14:55
• 2023 China BCI Industry Research Report.pdf
• 2023-12-02 10:20
• 2023 BCI Technology Application in Medical and Health Field White Paper – CAICT.pdf
• 2023-11-08 16:02
• CAICT: BCI Technology Application in Medical and Health Field White Paper (2023).pdf
• 2023-11-08 11:29
• Machinery Equipment Industry Robot Hardware Disassembly III: Flexible Sensors in Smart Robots and BCI Application Prospects – 20230618 – Guosheng Securities – 20 pages.pdf
• 2023-07-07 17:20
• BCI Industry Map – Tsinghua PBCSF.pdf
• 2023-07-07 06:34
• In-Depth Report – 20230618 – Guosheng Securities – Machinery Equipment Industry In-Depth_Robot Hardware Disassembly III_Flexible Sensors in Smart Robots and BCI Application Prospects_20 pages_2mb.pdf
• 2023-06-24 13:20
• Huibo Intelligent Investment Research – BCI Industry In-Depth: Industry Status, Market Development Analysis, Industry Chain and Related Companies Deep Analysis.pdf
• 2023-06-06 09:30
• 2022 BCI Value Trend Report – Arterial Orange.pdf
• 2023-03-05 09:16
• CAICT: BCI Overall Vision and Key Technology Research Report (2022).pdf
• 2022-11-29 17:03
• Yiou Think Tank – 2022 Global BCI Technology and Application Development Research Report.pdf
• 2022-11-04 10:04
• Eggshell Research Institute: 2022 BCI Industry Research Report.pdf
• 2022-10-08 23:28